Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

NorwayBack to Norway

Clinical trials in Levanger

14 clinical trials in Levanger, Norway. Every trial is listed in the EU Clinical Trials Register and updated daily.

NorwayOur site in NorwayKliniske-Studier.no(opens in a new tab)
Levanger at a glance
14
clinical trials
  • Paediatric trials0
  • Research sites0
Type of trial
Recruitment status
Quick filters

14 trials in Levanger

Open in trial search

Chronic kidney disease

Recruiting

Randomized Phase III trial of elecoglipron plus dapagliflozin on kidney outcomes and mortality in adults with chronic kidney disease

Registered drug
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:AZD5004
  • Sponsor:AstraZeneca AB

Systemic scleroderma

Recruiting

A double‑blind, placebo‑controlled trial of oral BI 1015550 in patients with systemic sclerosis

Investigational
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:BI 1015550
  • Sponsor:Boehringer Ingelheim Espana S.A.

Secondary immunodeficiency

Recruiting

Study of human normal immunoglobulin and teclistamab for infection prevention in adults with multiple myeloma receiving B-cell maturation antigen therapy

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Teclistamab
  • Sponsor:Takeda Development Center Americas Inc.

Neoplasm malignant

Recruiting

Study on Dabrafenib, Trametinib, and Imatinib for Patients with Rare and Hard-to-Treat Cancers

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Dabrafenib
  • Sponsor:Oslo University Hospital HF

Neoplasm malignant

Recruiting

Study on the Effectiveness of Tepotinib and Drug Combination for Patients with Advanced Cancer

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Alpelisib
  • Sponsor:Oslo University Hospital HF

Immune thrombocytopenia

Recruiting

Study Comparing Avatrombopag and Rituximab for Adults with Immune Thrombocytopenia Not Responding to Corticosteroids

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Avatrombopag
  • Sponsor:Ostfold Hospital Trust

Neck pain

Recruiting

Study on Chiropractic Therapy and Ibuprofen for Acute Neck Pain in Adults

Registered drug
Countries:NorwayNorway
  • Participants:18–64 years
  • Substances:Ibuprofen
  • Sponsor:Akershus University Hospital

Small cell lung cancer limited stage

Not yet recruiting

Durvalumab after chemoradiation for patients with limited‑stage small cell lung cancer: a randomized trial of high‑dose versus standard thoracic radiation

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Norwegian University Of Science And Technolology

Primary adrenal insufficiency

Not recruiting

Study on Quality of Life in Patients Aged 16-80 with Primary Adrenal Insufficiency Using Hydrocortisone (Plenadren) and Cortisone

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:0–17 years · 18–64 years
  • Substances:Cortisone
  • Sponsor:Helse Bergen HF

Plasma cell myeloma

Not recruiting

Study on Early Treatment for Multiple Myeloma Relapse Using Carfilzomib, Bortezomib, Daratumumab, Lenalidomide, and Dexamethasone in Patients with MRD Negativity

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Oslo University Hospital HF

Crohn's disease

Not recruiting

Study on the Effectiveness and Safety of Risankizumab for Patients with Moderate to Severe Crohn's Disease

Investigational
Countries:NorwayNorway
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Risankizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Small cell lung cancer extensive stage

Not recruiting

Study on the Effect of Adding Thoracic Radiotherapy to Durvalumab and Chemotherapy for Patients with Extensive Stage Small-Cell Lung Cancer

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Norwegian University Of Science And Technolology

Other cities in Norway

The busiest research cities in the country

All 54 cities in Norway

Clinical research in Levanger

What the registry says about research in the country

01 Oncology Research

Groundbreaking studies focusing on precision cancer medicine for rare and hard-to-treat cancers, including innovative approaches to drug repurposing and targeted therapies.

  • Rare Cancer Treatment
  • Advanced Malignancies
  • Targeted Anti-cancer Drugs

Research aims to improve treatment outcomes through personalized therapeutic approaches.

02 Lung Cancer Studies

Comprehensive research into small-cell lung cancer and non-small cell lung cancer, evaluating innovative combination therapies including immunotherapy and radiotherapy.

  • Extensive Stage SCLC
  • Limited Disease SCLC
  • Advanced NSCLC

Studies focus on improving survival rates through combined treatment modalities.

03 Autoimmune Conditions

Clinical investigations of treatments for Crohn's Disease and Immune Thrombocytopenia, testing new therapeutic approaches and maintenance strategies.

  • Inflammatory Bowel Disease
  • Blood Disorders
  • Long-term Treatment Efficacy

Evaluating novel therapies for chronic autoimmune conditions with focus on long-term management.

Back to NorwayAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.